Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
March 03, 2025
March 03, 2025
LONDON, England, March 3 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
* If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
* Submissions based on data from positi . . .
* * *
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
* If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
* Submissions based on data from positi . . .